ImmuCell Corporation (ICCC) vs Rani Therapeutics Holdings, Inc. (RANI)
- ImmuCell Corporation ICCC 10.75 +1.80%
- Rani Therapeutics Holdings, Inc. RANI 0.64 −5.88%
ImmuCell Corporation and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. ImmuCell Corporation and Rani Therapeutics Holdings, Inc. are of similar size ($95.9M and $94.8M). Rani Therapeutics Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 126×. Rani Therapeutics Holdings, Inc. grew revenue faster over the last twelve months: 78.7% against 8.49%. ImmuCell Corporation has the higher net margin (2.57% vs −597.0%) and the higher return on invested capital (7.84% vs 0.00%). Across the 17 metrics below, ImmuCell Corporation leads on 11 and Rani Therapeutics Holdings, Inc. on 6.
Valuation
Profitability
| Metric | ICCC | RANI | Biotechnology median |
|---|---|---|---|
| Gross margin | 40.32% | 100.00% | 65.16% |
| Operating margin | 12.60% | (652.78%) | 0.00% |
| Net margin | 2.57% | (596.97%) | 0.00% |
| Free cash flow margin | 13.79% | (402.83%) | 0.00% |
| Return on equity | 2.57% | (155.24%) | (56.36%) |
| Return on assets | 1.69% | (77.54%) | (48.04%) |
| Return on invested capital | 7.84% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack